AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

BACKGROUND: Oral imatinib has been shown to be effective, but poorly tolerated, in patients with advanced pulmonary arterial hypertension (PAH). To maintain efficacy while improving tolerability, AV-101, a dry powder inhaled formulation of imatinib, was developed to deliver imatinib directly to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillies, Hunter, Niven, Ralph, Dake, Benjamin T., Chakinala, Murali M., Feldman, Jeremy P., Hill, Nicholas S., Hoeper, Marius M., Humbert, Marc, McLaughlin, Vallerie V., Kankam, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009698/
https://www.ncbi.nlm.nih.gov/pubmed/36923571
http://dx.doi.org/10.1183/23120541.00433-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009698/
https://www.ncbi.nlm.nih.gov/pubmed/36923571
http://dx.doi.org/10.1183/23120541.00433-2022

Ejemplares similares